{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:33:10Z","timestamp":1773189190427,"version":"3.50.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Human adenovirus (Ad)-vectored vaccines require viruses that can internalize into host cells and express the vaccine antigen. Evaluation of the expressed antigen in animal cells is a critical step in preclinical trials of viral vaccines. Due to the species specificity of Ads, it is difficult to find a suitable animal model. Thus, in this study, we compared the efficacy of Ad 11 prototype (Ad11p)-mediated green fluorescence protein (GFP) expression in cell lines of dog (MDCK), hamster (CHO), and mouse (McCoy and C127). Although these cell lines did not express the known primary cellular receptors for Ad11p virus infection (i.e., CD46), Ad11pE1GFP could infect and express GFP with various efficacies. For instance, it manifested relatively higher GFP expression in MDCK than in CHO, McCoy, and C127. However, infection leading to efficient viral release was not observed in any of the studied cell lines. The apparent differences were attributed to particularities of mouse and hamster cell lines, which might have led to the repression of viral DNA synthesis and to the low level of GFP expression mediated by Ad11pe3GFP. Moreover, our results revealed that undetectable hexon protein hampered the assembly of virus particles in CHO and MDCK cells. Ad11p differed from Ad5 in the ability for viral DNA synthesis when infecting CHO cells. Although a defective Ad has been successfully developed for SARS-CoV-2 vaccines in clinical applications, it has been difficult to generate one that can be used as an oral SARS-CoV-2 vaccine. Fortunately, our replication-competent Ad 11p vector might solve this problem. Regarding the use of Ad-vector candidates for vaccine purposes, this study demonstrates the selection of animal cell lines and determination of suitable virus doses in <jats:italic>in vitro<\/jats:italic> experiments.<\/jats:p>","DOI":"10.3389\/fmicb.2021.698999","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T06:40:36Z","timestamp":1635316836000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Susceptibility of Dog, Hamster, and Mouse Cells to the Replication-Competent Adenovirus 11p E1\/E3 Green Fluorescence Protein Vector Has Implications for the Selection of Animal Vaccine Models"],"prefix":"10.3389","volume":"12","author":[{"given":"Madhuri","family":"Gokumakulapalle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Fang","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1128\/AAC.00203-10","article-title":"Small-molecule screening using a whole-cell viral replication reporter gene assay identifies 2-{[2-(benzoylamino)benzoyl]amino}-benzoic acid as a novel antiadenoviral compound.","volume":"54","author":"Andersson","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"8802","DOI":"10.1073\/pnas.91.19.8802","article-title":"An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3.","volume":"91","author":"Bett","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B3","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/d41586-020-01221-y","article-title":"The race for coronavirus vaccines: a graphical guide.","volume":"580","author":"Callaway","year":"2020","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1016\/j.vaccine.2013.05.016","article-title":"Prospects for oral replicating adenovirus-vectored vaccines.","volume":"31","author":"Deal","year":"2013","journal-title":"Vaccine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41392-020-00352-y","article-title":"A systematic review of SARS-CoV-2 vaccine candidates.","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduct Target. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial.","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e00237","DOI":"10.1128\/JVI.00237-19","article-title":"Oral Vaccination with Replication-Competent Adenovirus in Mice Reveals Dissemination of the Viral Vaccine beyond the Gastrointestinal Tract.","volume":"93","author":"Goffin","year":"2019","journal-title":"J. Virol."},{"key":"B8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.virol.2016.04.029","article-title":"Replication-competent human adenovirus 11p vectors can propagate in Vero cells.","volume":"495","author":"Gokumakulapalle","year":"2016","journal-title":"Virology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S1473-3099(12)70345-6","article-title":"Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study.","volume":"13","author":"Gurwith","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/infdis\/jiz241","article-title":"Immunogenicity, Lot Consistency, and Extended Safety of rVSVDeltaG-ZEBOV-GP Vaccine: a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.","volume":"220","author":"Halperin","year":"2019","journal-title":"J. Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1128\/JVI.76.9.4612-4620.2002","article-title":"Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease.","volume":"76","author":"Havenga","year":"2002","journal-title":"J. Virol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.vaccine.2012.12.029","article-title":"History of the restoration of adenovirus type 4 and type 7 vaccine, live oral (Adenovirus Vaccine) in the context of the Department of Defense acquisition system.","volume":"31","author":"Hoke","year":"2013","journal-title":"Vaccine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1006\/biol.1993.1089","article-title":"Albert B. Sabin and the development of oral poliovaccine.","volume":"21","author":"Horaud","year":"1993","journal-title":"Biologicals"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1128\/JVI.80.7.3549-3558.2006","article-title":"Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species.","volume":"80","author":"Jogler","year":"2006","journal-title":"J. Virol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/infdis\/160.2.191","article-title":"Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs.","volume":"160","author":"Katz","year":"1989","journal-title":"J. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1038\/mt.2009.202","article-title":"Adenovirus virion stability and the viral genome: size matters.","volume":"17","author":"Kennedy","year":"2009","journal-title":"Mol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/S0264-410X(97)00118-7","article-title":"Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 2. Immunogenicity in poor responders to hepatitis B vaccines.","volume":"15","author":"Leroux-Roels","year":"1997","journal-title":"Vaccine"},{"key":"B18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ijc.2910170110","article-title":"A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells.","volume":"17","author":"Lieber","year":"1976","journal-title":"Int. J. Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia.","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1128\/MCB.1.3.208","article-title":"Chinese hamster ovary cells replicate adenovirus deoxyribonucleic acid.","volume":"1","author":"Longiaru","year":"1981","journal-title":"Mol. Cell. Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e140794","DOI":"10.1172\/JCI140794","article-title":"A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity.","volume":"131","author":"Matsuda","year":"2021","journal-title":"J. Clin. Invest."},{"key":"B22","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1006\/viro.1997.8904","article-title":"Two closely related adenovirus genome types with kidney or respiratory tract tropism differ in their binding to epithelial cells of various origins.","volume":"240","author":"Mei","year":"1998","journal-title":"Virology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1128\/jvi.70.6.3688-3697.1996","article-title":"Epitopes and hemagglutination binding domain on subgenus B:2 adenovirus fibers.","volume":"70","author":"Mei","year":"1996","journal-title":"J. Virol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.virol.2016.07.026","article-title":"Complete replication-competent adenovirus 11p vectors with E1 or E3 insertions show improved heat stability.","volume":"497","author":"Mei","year":"2016","journal-title":"Virology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/infdis\/150.1.92","article-title":"A new animal model for human respiratory tract disease due to adenovirus.","volume":"150","author":"Pacini","year":"1984","journal-title":"J. Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"7909","DOI":"10.1128\/JVI.72.10.7909-7915.1998","article-title":"The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F.","volume":"72","author":"Roelvink","year":"1998","journal-title":"J. Virol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/j.1348-0421.1983.tb00638.x","article-title":"A rapid and simple method for preparation of adenovirus DNA from infected cells.","volume":"27","author":"Shinagawa","year":"1983","journal-title":"Microbiol. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1128\/JVI.01644-08","article-title":"DNA genome size affects the stability of the adenovirus virion.","volume":"83","author":"Smith","year":"2009","journal-title":"J. Virol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-05-3497","article-title":"Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors.","volume":"66","author":"Thomas","year":"2006","journal-title":"Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.virol.2012.10.034","article-title":"A mouse mammary epithelial cell line permissive for highly efficient human adenovirus growth.","volume":"435","author":"Wu","year":"2013","journal-title":"Virology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.18632\/oncotarget.26754","article-title":"An oncolytic adenovirus 11p vector expressing adenovirus death protein in the E1 region showed significant apoptosis and tumour-killing ability in metastatic prostate cells.","volume":"10","author":"Wu","year":"2019","journal-title":"Oncotarget"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.698999\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T06:40:42Z","timestamp":1635316842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.698999\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":32,"alternative-id":["10.3389\/fmicb.2021.698999"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2021.698999","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"article-number":"698999"}}